Skip to main content

Advertisement

SpringerLink
Log in

Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma

  • Short Communication
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Perioperative chemotherapy plus surgery improves survival compared to surgery alone in GE junctional (GEJ) and gastric adenocarcinomas. The docetaxel/cisplatin/5-fluorouracil (DCF) combination is superior to CF in patients with metastatic gastric cancer. We retrospectively evaluated the safety and efficacy of preoperative DCF chemotherapy in patients with locally advanced gastric and GEJ cancer. Twenty-one gastric and 10 gastroesophageal junctional (GEJ) cancer patients received 2–3 cycles of preoperative docetaxel 75 mg/m2 and cisplatin 75 mg/m2 on day 1, 5-FU 750 mg/m2 (continuous infusion) on days 1–5 every 3 weeks. Clinical response was evaluated by comparing pre- and postchemotherapy CT scans. Overall survival (OS) and progression-free survival (PFS) were calculated from the initiation of chemotherapy. None of the patients achieved complete clinical remission while 11 (35%) patients achieved partial clinical remission. Ten patients with GEJ cancer (100%) and 13 with gastric cancer (62%) underwent curative surgery (P = 0.023). Seventeen (55%) patients experienced grade 3–4 chemotherapy-related adverse events. The most common adverse events were anemia, nausea/vomiting, diarrhea, and febrile neutropenia. At a median follow-up of 17.0 months, median OS and PFS were 26.1 months (95% CI: 22.7–29.5) and 18.8 months (95% CI: 9.9–27.7), respectively. The DCF regimen is active in patients with gastric and GEJ adenocarcinoma in the preoperative setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Schuhmacher CP, Fink U, Becker K, Busch R, Dittler HJ, Mueller J, et al. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Cancer. 2001;91:918–27.

    Article  PubMed  CAS  Google Scholar 

  2. Ott K, Sendler A, Becker K, Dittler HJ, Helmberger H, Busch R, et al. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer. Gastric Cancer. 2003;6:159–67.

    Article  PubMed  CAS  Google Scholar 

  3. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–21.

    Article  PubMed  CAS  Google Scholar 

  4. Einzig AI, Neuberg D, Remick SC, Karp DD, O’Dwyer PJ, Stewart JA, et al. Phase II trial of docetaxel in patients with adenocarcinoma of the upper gastrointestinal tract. Med Oncol. 1996;13:1263–6.

    Google Scholar 

  5. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, et al. Docetaxel in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer. 1994;70:380–3.

    Article  PubMed  CAS  Google Scholar 

  6. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, et al. Docetaxel-cisplatin (TC): an effective drug combination in gastric carcinoma. Ann Oncol. 2000;11:301–6.

    Article  PubMed  CAS  Google Scholar 

  7. Constenla M, Garcia-Arroyo R, Lorenzo I, Carrete N, Campos B, Palacios P. Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study. Gastric Cancer. 2002;5:142–7.

    Article  PubMed  CAS  Google Scholar 

  8. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III Study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer. J Clin Oncol. 2006;24:4991–7.

    Article  PubMed  Google Scholar 

  9. Roth DA, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007;25:3217–23.

    Article  PubMed  CAS  Google Scholar 

  10. Ajani JA, Van Cutsem E, Moiseyenko V, Tjulandin S, Fodor M, Majlis A, et al. Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325). 2003 (ASCO Annual Meeting, abstract 999).

  11. Ma Y, Qin H, Zheng Q, Wang Y, Wang Z, Yang Z. Neoadjuvant chemotherapy with a combination of docetaxel, cisplatin, fluorouracil, and leucovorin in nonresectable advanced gastric cancer. Med Oncol. 2010;27(4):1089–95.

    Article  PubMed  CAS  Google Scholar 

  12. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Filho SC, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005;23:5660–7.

    Article  PubMed  CAS  Google Scholar 

  13. Helmberger H, Baum U, Dittler HJ, Sendler A, Schulte B, Herter B, et al. Adenocarcinoma of the gastro-esophageal junction: CT for monitoring during neoadjuvant chemotherapy. Eur J Radiol. 1996;23:107–10.

    Article  PubMed  Google Scholar 

  14. Guo MG, Zheng Q, Cheng Z, Wang Y, Feng CN, Yang Z. The combination of docetaxel and cisplatin plus fluorouracil as neoadjuvant chemotherapy in the treatment of T4 stage gastric cancer. Surg Oncol. 2010;19(1):1–3.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

Authors declare no conflicts of interest or pertinent financial relationships.

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Ave St, Miami, FL, 3300, USA

    Ulas Darda Bayraktar, Soley Bayraktar, Peter Hosein, Caio Max S. Rocha-Lima & Alberto J. Montero

  2. University of Miami Miller School of Medicine, Miami, FL, USA

    Emerson Chen

  3. Division of Surgical Oncology, Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA

    Leonidas G. Koniaris

Authors
  1. Ulas Darda Bayraktar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Soley Bayraktar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Hosein
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emerson Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Leonidas G. Koniaris
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Caio Max S. Rocha-Lima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alberto J. Montero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulas Darda Bayraktar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bayraktar, U.D., Bayraktar, S., Hosein, P. et al. Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma. Med Oncol 29, 1707–1710 (2012). https://doi.org/10.1007/s12032-011-0093-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-0093-8

Keywords

Search

Navigation